Oracle stock falls after report reveals thin margins in AI cloud business
Propanc Biopharma Inc. (PPCB) announced plans to establish a digital asset treasury exceeding $100 million over the next twelve months, according to a company statement following its fiscal year-end filing with the Securities and Exchange Commission.
The biopharmaceutical company, which focuses on developing treatments for recurring and metastatic cancer, completed its initial public offering and uplisted to NASDAQ on August 14, 2025. The company raised $4 million in gross proceeds through an offering of 1 million common shares with underwriter D Boral Capital.
Chief Executive Officer James Nathanielsz stated the company intends to join more than 200 public companies that currently hold digital assets in their corporate treasuries. "These Digital Asset Treasury Companies hold billions of dollars in cryptocurrencies, primarily Bitcoin, but increasingly also Ethereum, Solana, and other altcoins, as a strategic corporate asset," Nathanielsz said.
The company reported significant financial changes for the fiscal year ending June 30, 2025. Total assets increased to $19.6 million from approximately $72,000 in the previous period. Stockholders’ equity rose to $13.9 million from a deficit of $3.8 million. The asset growth stems primarily from prepaid service contracts related to market awareness, advisory, accounting, finance, manufacturing, and research and development activities.
Propanc develops treatments using pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. The company stated it anticipates various development milestones by the end of 2025 and throughout 2026 while engaging in collaborative efforts regarding its clinical pipeline.
The Melbourne, Australia-based company filed its annual 10-K report on September 29, 2025, covering the reporting period that concluded June 30, 2025.